Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Scholar Rock Holding's Apitegromab?
Apitegromab is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase III program in Spinal Muscular Atrophy...
Data Insights
Risk adjusted net present value: What is the current valuation of Scholar Rock Holding's Linavonkibart?
Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Oropharyngeal Cancer. According...